Effect of a synthetic matrix metalloproteinase inhibitor (ONO-4817) on neointima formation in hypercholesterolemic hamsters

Journal of Cardiovascular Pharmacology

Volumn 44, Issue 1, 2004, Pages 57-65

  Matsuno, Hiroyuki ^a,b   Ishisaki, Akira ^a   Nakajima, Keiichi ^a   Kozawa, Osamu ^a  

^a GIFU UNIVERSITY   (Japan)

^b GIFU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Hypercholesterolemia; Matrix Metalloproteinase 12; Migration; Neointima; SMCs

Indexed keywords

5 ETHOXYMETHOXY N HYDROXY 2 METHYL 4 (4 PHENOXYBENZAMIDO)PENTANAMIDE; MATRIX METALLOPROTEINASE INHIBITOR; N HYDROXY 5 ETHOXYMETHYLOXY 2 METHYL 4 (4 PHENOXYLBENZOYL)AMINOPENTANAMIDE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTERY CATHETERIZATION; ARTERY INTIMA PROLIFERATION; ARTICLE; BLOOD VESSEL INJURY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DNA SYNTHESIS; ENDOTHELIUM INJURY; HAMSTER; HYPERCHOLESTEROLEMIA; IN VITRO STUDY; INTIMA; MALE; MAZE TEST; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; SMOOTH MUSCLE FIBER; STENOSIS; WESTERN BLOTTING;

ANIMALS; CAROTID ARTERY INJURIES; CELL MOVEMENT; CELLS, CULTURED; CRICETINAE; HYPERCHOLESTEROLEMIA; MALE; MATRIX METALLOPROTEINASE 12; MATRIX METALLOPROTEINASES; METALLOENDOPEPTIDASES; MUSCLE, SMOOTH, VASCULAR; PHENYL ETHERS; TUNICA INTIMA;

EID: 3042701056     PISSN: 01602446     EISSN: None     Source Type: Journal    
DOI: 10.1097/00005344-200407000-00008     Document Type: Article

References (34)

1. Stetler-Stevenson WG, Liotta LA, Kleiner DE Jr. Extracellular matrix 6: role of matrix metalloproteinases in tumor invasion and metastasis. FASEB J. 1993;7:1434-1441.
2. Kirchheimer JC, Binder BR, Remold HG. Matrix-bound plasminogen activator inhibitor type 1 inhibits the invasion of human monocytes into interstitial tissue. J Immunology. 1990;145:1518-1522.
3. Talhouk RS, Bissell MJ, Werb Z. Coordinated expression of extracellular matrix-degrading proteinases and their inhibitors regulates mammary epithelial function during involution. J Cell Biol. 1992;118:1271-1282.
4. Galis ZS, Sukhova GK, Lark MW, et al. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest. 1994;94:2493-2503.
5. Henney AM, Wakeley PR, Davies MJ, et al. Localization of stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc Natl Acad Sci USA. 1991;88:8154-8158.
6. Brown DL, Hibbs MS, Kearney M, et al. Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. Circulation. 1995;91:2125-2131.
7. Bendeck MP, Zempo N, Clowes AW, et al. Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ Res. 1994;75:539-545.
8. Bendeck MP, Irvin C, Reidy MA. Inhibition of matrix metalloproteinase activity inhibits smooth muscle cell migration but not neointimal thickening after arterial injury. Circ Res. 1996;78:38-43.
9. Matsumoto S, Kobayashi T, Katoh M, et al. Expression and localization of matrix metalloproteinase-12 in the aorta of cholesterol-fed rabbits: relationship to lesion development. Am J Pathol. 1998;153:109-119.
10. Banda MJ, Werb Z. Mouse macrophage elastase. Purification and characterization as a metalloproteinase. Biochem J. 1981;193:589-605.
11. Gronski TJ Jr, Martin RL, Kobayashi DK, et al. Hydrolysis of a broad spectrum of extracellular matrix proteins by human macrophage elastase. J Biol Chem. 1997;272:12189-12194.
12. Chandler S, Cossins J, Lury J, et al. Macrophage metalloelastase degrades matrix and myelin proteins and processes a tumour necrosis factor-alpha fusion protein. Biochem Biophys Res Com. 1996;228:421-429.
13. Matsuno H, Kozawa O, Niwa M, et al. Characterization of simple and reproducible vascular stenosis model in hypercholesterolemic hamsters. Lipids. 2001;36:453-460.
14. Matsuno H, Stassen JM, Vermylen J, et al. Inhibition of integrin function by a cyclic RGD-containing peptide prevents neointima formation. Circulation. 1994;90:2203-2206.
15. Yamada A, Uegaki A, Nakamura T, et al. ONO-4817, an orally active matrix metalloproteinase inhibitor, prevents lipopolysaccharide-induced proteoglycan release from the joint cartilage in guinea pigs. Inflamm Res. 2000;49:144-146.
16. Mori T, Yamasaki S, Masui F, et al. Suppression of the development of experimentally induced uterine adenomyosis by a novel matrix metalloproteinase inhibitor, ONO-4817, in mice. Exp Biol Med. 2001;226:429-433.
17. Shiraga M, Yano S, Yamamoto A, et al. Organ heterogeneity of host-derived matrix metalloproteinase expression and its involvement in multiple-organ metastasis by lung cancer cell lines. Cancer Res. 2002;62:5967-5973.
18. Matsuno H, Stassen JM, Moons L, et al. Neointima formation in injured hamster carotid artery is effectively prevented by the combination G4120 and quinapril. Thromb Haemost. 1996;76:263-269.
19. Majesky MW, Reidy MA, Bowen-Pope DF, et al. PDGF ligand and receptor gene expression during repair of arterial injury. J Cell Biol. 1990;111:2149-2158.
20. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680-685.
21. Kato K, Ito H, Hasegawa K, et al. Modulation of the stress-induced synthesis of hsp27 and alpha B-crystallin by cyclic AMP in C6 rat glioma cells. J Neurochem. 1996;66:946-950.
22. Annabi B, Shedid D, Ghosn P, et al. Differential regulation of matrix metalloproteinase activities in abdominal aortic aneurysms. J Vasc Surg. 2002;35:539-546.
23. Ross R, Glomset J, Kariya B, et al. A Platelet-Dependent Serum Factor that Stimulates The Proliferation of Arterial Smooth Muscle Cells in vitro. Proc Natl Acad Sci U S A. 1974;71:1207-1210.
24. Matsuno H, Kozawa O, Niwa M, et al. GR144053, a fibrinogen receptor antagonist, enhances the suppression of neointima formation by losartan, an angiotensin II receptor antagonist, in the injured carotid artery of hamster. Br J Pharmacol. 1997;122:1099-1104.
25. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990s. Nature. 1993;362:801-809.
26. Zempo N, Koyama N, Kenagy RD, et al. Regulation of vascular smooth muscle cell migration and proliferation in vitro and in injured rat arteries by a synthetic matrix metalloproteinase. Arterioscler Thromb Vasc Biol. 1996;16:28-33.
27. Clowes AW, Schwartz SM. Significance of quiescent smooth muscle migration in the injured rat carotid artery. Circ Res. 1985;56:139-145.
28. White FC, Carroll SM, Magnet A, et al. Coronary collateral development in swine after coronary artery occlusion. Circ Res. 1992;71:1490-1500.
29. Newby AC, Southgate KM, Davies M. Extracellular matrix degrading metalloproteinases in the pathogenesis of arteriosclerosis. Basic Res Cardiol. 1994;89:59-70.
30. Lamblin N, Bauters C, Hermant X, et al. Polymorphisms in the promoter regions of MMP-2, MMP-3, MMP-9 and MMP-12 genes as determinants of aneurysmal coronary artery disease. J Am Coll Cardiol. 2002;40:43-48.
31. Matsuno H, Kozawa O, Niwa M, et al. Inhibition of von Willebrand factor binding to platelet GP Ib by a fractionated aurintricarboxylic acid prevents restenosis after vascular injury in hamster carotid artery. Circulation. 1997;96:1299-1304.
32. Brener SJ, Barr LA, Burchenal JE, et al. Effect of abciximab on the pattern of reperfusion in patients with acute myocardial infarction treated with primary angioplasty. Am J Cardiol. 1999;84:728-730.
33. Brener SJ, Barr LA, Burchenal JE, et al. Randomized, placebo-controlled trial of platelet glycoprotein IIb/IIIa blockade with primary angioplasty for acute myocardial infarction. ReoPro and Primary PTCA Organization and Randomized Trial (RAPPORT) Investigators. Circulation. 1998;98:734-741.
34. Puyraimond A, Fridman R, Lemesle M, et al. MMP-2 colocalizes with caveolae on the surface of endothelial cells. Exp Cell Res. 2001;262:28-36.